Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH). Specifically, it represents an analog of the ACTH(4-10) sequence – Met-Glu-His-Phe-Pro-Gly-Pro – stabilized with a C-terminal Pro-Gly-Pro (PGP) extension that confers resistance to enzymatic degradation. Originally developed in Russia at the Institute of Molecular Genetics, Semax has been the subject of extensive preclinical investigation for its neurotrophic, neuroprotective, and cognitive-modulating properties.
Unlike many research peptides derived from peripheral endocrine hormones, Semax demonstrates pronounced central nervous system activity following intranasal administration in rodent models, making it a particularly useful tool for researchers studying brain-derived neurotrophic factor (BDNF) signaling, neuroinflammation, and ischemic injury models.
Mechanism of Action: BDNF Upregulation and TrkB Receptor Engagement
The primary mechanism underlying Semax’s neurotrophic effects involves upregulation of BDNF and its high-affinity receptor TrkB in critical hippocampal and basal forebrain circuits. In a foundational study, Dolotov et al. (2006) demonstrated that a single intranasal application of Semax in rats produced a maximal 1.4-fold increase in BDNF protein levels and a 1.6-fold increase in TrkB tyrosine phosphorylation in the hippocampus, changes that peaked at 1 hour post-administration and coincided with upregulated expression of BDNF exon III mRNA (PMID: 16996037; DOI: 10.1016/j.brainres.2006.08.008).
Additionally, specific and saturable binding sites for tritiated Semax have been identified on rat basal forebrain cell membranes, suggesting direct receptor-mediated activity rather than purely indirect signaling. This binding is calcium-dependent and reversible – hallmarks of a pharmacologically specific interaction rather than non-specific membrane association.
Beyond BDNF, Semax appears to modulate dopaminergic and serotonergic transmission in subcortical regions, providing a plausible mechanistic account for the cognitive and behavioral phenotypes observed in rodent learning paradigms following peptide administration.
Preclinical Evidence: Neuroprotection in Ischemia-Reperfusion Models
A substantial portion of the Semax preclinical literature focuses on cerebral ischemia models, where the peptide has been assessed using transient middle cerebral artery occlusion (tMCAO) and ischemia-reperfusion protocols in rodents.
A 2021 proteomic study by Sudarkina et al. published in International Journal of Molecular Sciences used two-dimensional gel electrophoresis and mass spectrometry to characterize the brain protein expression profile following Semax treatment in rats subjected to ischemia-reperfusion injury. The analysis revealed that Semax administration was associated with differential expression of proteins involved in cytoskeletal organization, energy metabolism, and neuronal stress response pathways – supporting a broad neuroprotective transcriptional program rather than a single-target effect. (PMID: 34201112; DOI: 10.3390/ijms22126179)
More recently, a 2023 study in Genes (Basel) by Filippenkov et al. assessed the impact of Semax and a related ACTH analog on immune gene expression patterns in rat brain tissue at early post-stroke time points. RNA-seq analysis identified Semax-associated downregulation of pro-inflammatory mediators and upregulation of neuroprotective gene clusters in the ischemic penumbra region – a finding consistent with the peptide’s proposed role in limiting secondary neuroinflammatory cascades after ischemic insult. (PMID: 37510287; DOI: 10.3390/genes14071382)
Together, these findings support a model in which Semax acts at multiple regulatory levels – neurotrophic signaling, neuroinflammation, and energy metabolism – to confer neuroprotective effects in preclinical ischemia models.
Frequently Asked Questions
What is Semax used for in research?
In preclinical research, Semax is studied primarily as a tool for investigating BDNF-TrkB signaling, neuroprotection in ischemia-reperfusion injury models, and neuroinflammatory gene expression in the rodent brain. It is classified as a research compound and is not approved for human therapeutic use outside Russia.
How does Semax relate to ACTH structurally?
Semax is a synthetic analog derived from the ACTH(4-7) fragment (Met-Glu-His-Phe), extended with a stabilizing Pro-Gly-Pro C-terminal tripeptide. This modification increases metabolic stability compared to the native ACTH fragment while preserving CNS activity. Unlike full-length ACTH, Semax does not bind corticosteroid receptors or stimulate adrenal cortisol production at pharmacologically relevant doses in rodent models.
What is the BDNF connection in Semax research?
BDNF (brain-derived neurotrophic factor) is a key regulator of synaptic plasticity, neuronal survival, and hippocampal neurogenesis. Preclinical studies have shown that Semax upregulates BDNF protein expression and promotes TrkB receptor phosphorylation in hippocampal tissue, providing a mechanistic basis for investigating its effects in learning and memory paradigms in rodent models.
Is Semax the same as Selank?
No. Semax and Selank are distinct synthetic peptides developed in the same Russian research program. Semax is derived from ACTH(4-10) and is primarily associated with neurotrophic and neuroprotective signaling. Selank is a synthetic analog of tuftsin (Thr-Lys-Pro-Arg) and is studied primarily for its anxiolytic and GABAergic modulation properties. Both are used in preclinical CNS research but have different molecular targets and research profiles.
Where can I find peer-reviewed research on Semax?
A growing body of peer-reviewed research on Semax is indexed in PubMed. Key search terms include “Semax ACTH neuroprotection,” “ACTH(4-7)PGP ischemia,” and “Semax BDNF hippocampus.” Most of the primary literature originates from the Institute of Molecular Genetics and affiliated Russian research institutions, with a subset of studies published in international journals indexed in MEDLINE.
This content is for informational and educational purposes only. All products sold by Core Research Peptides are for research use only and not for human consumption. This article does not constitute medical advice, and no information presented here should be interpreted as a recommendation for any therapeutic, clinical, or self-administration use.
In stock now
Adamax 10mg, in stock in the United States
Core Research Peptides stocks Adamax 10mg at $62 a vial with published bundle pricing at two, three and five units. Orders placed before 4PM ET dispatch the same day, seven days a week.
Read the Adamax buying guideView Adamax 10mgFree research guide for this compound at coreresearchpeptides.com/guides.
